Navigation Links
DSM Joins International Response to Flooding in Australia
Date:1/27/2011

PARSIPPANY, N.J., Jan. 27, 2011 /PRNewswire/ -- Significant flooding occurred in many areas of Queensland during late December 2010 and early January 2011.  Thousands of residents were affected.  A disaster relief appeal, the 'Premier's Disaster Relief Appeal', was launched on 29 December 2010, by Premier of Queensland, Anna Bligh.  DSM recognizes the efforts of Queenslanders who pitched in to help their fellow citizens clean-up in the wake of the floods and help families in need, many of whom lost everything.  

In May of 2010 DSM announced the signing of agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.  Currently under construction the facility will be located on the Princess Alexandra Hospital Campus, 5.5 kilometers from the center of Brisbane. Karen King, President of DSM Biologics commented, "We are extremely concerned about the effects of the severe flooding in Queensland and the need for support of those impacted."  

Professor Peter Gray, Director of the Australian Institute of Bioengineering & Nanotechnology which is based in Queensland, visited DSM soon after the flooding.  According to Professor Gray, "The relief appeal will make a significant difference by helping many in need as Queensland battles to recover from the flooding.  I am delighted to have DSM among our supporters."  Alexander Wessels, President and CEO, DSM Pharmaceutical Products, stated, "As a responsible corporate citizen around the world, DSM is committed to the communities in which we work and live. This is our humble gesture to aid those in need through the auspices of the Premier's appeal."

For more information about supporting the Premier's Disaster Relief Appeal, visit www.qld.gov.au/floods/  

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com For more information:DSMGuy TieneDirector, marketing and Communicationstel. +1 973 257 8160guy.tiene@dsm.com  DSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
2. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
3. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
4. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as COO
5. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
6. Joseph J. LaRosa Joins Nycomed US Inc.
7. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
8. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
9. LitePoint Joins Continua Health Alliance
10. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
11. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- Andre, DiMino, CEO of ADM Tronics Unlimited, Inc. (OTCQB: ... and products, commented on ADMT,s third quarter fiscal year ... the Company,s quarterly report on Form 10Q available at ... stated "During the quarter ended December 31, 2016 we ... portion of our engineering efforts into the development of ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... infarction partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605670-summary/view-report.html Description The ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... 22, 2017 Summary Provides ... partnering deals and agreements entered into by the ... report: http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... skipping doses or not filling a prescription because they could not afford to ... problems getting medications were 30-60%*. At the same time, hospitals, pharmacies, ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael ... new media platform connecting healthcare technology professionals and other key stakeholders with an ... quarterly publication starting on March 1, announced Michael J. Hennessy, Jr., president of ...
Breaking Medicine News(10 mins):